Pimecrolimus for the treatment of inflammatory skin disease

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 643-655

  Wolff, Klaus ^a   Stuetz, Anton ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Novartis Inst for Biomedical Res   (Austria)

Author keywords

Ascomycine; Atopic; Calcineurin inhibitors; Dermatitis; Pimecrolimus; Psoriasis

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; ASCOMYCIN; CALCINEURIN INHIBITOR; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID ETHYL ESTER; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PSORALEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RETINOID; TACROLIMUS; TAZAROTENE; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; CHEILITIS; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; ERYTHEMA; FLU LIKE SYNDROME; GENOTOXICITY; GROWTH RETARDATION; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOREACTIVITY; KIDNEY DYSFUNCTION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; METABOLIC DISORDER; MYALGIA; NAUSEA; NONHUMAN; PHARMACOGENOMICS; PHOTOTHERAPY; PHOTOTOXICITY; PRURITUS; PSORIASIS; PUVA; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SJOEGREN SYNDROME; SKIN ATROPHY; SKIN CANCER; SKIN INFLAMMATION; SKIN IRRITATION; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; HUMANS; PSORIASIS; TACROLIMUS;

EID: 1542400364     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.643     Document Type: Review

References (82)

1. LEUNG DYM, EICHENFIELD LF, BOGUNIEWICZ M: Atopic dermatitis (atopic eczema). In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):1180-1194.
2. LEUNG DYM: AtNpic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Immunol. (2000) 105:860-876.
3. BACH JF: The effect of infections on susceptibility to autoimmune and allergic disease. N. Engl. J. Med. (2002) 347:911-920.
4. EICHENFIELD LF, HANIFIN JM, BECK LA et al.: Atopic dermatitis and asthma: Parallels in the evolution of treatment. Pediatrics (2003) 111:608-616.
5. ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. (2002) 347:1151-1160.
6. LEUNG DY, HANIFIN JM, CHARLESWORTH EN et al.: Disease management of atopic dermatitis: A practice parameter. Jount Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann. Allergy Astma Immunol. (1997) 79:197-211.
7. BOGUNEIWICZ M, LEUNG DYM: New concepts in atopic dermatitis. Compr. Ther. (1996) 22:144-151.
8. CHARMAN CR, MORRIS AD, WILLIAMS HC: Topical corticosteroid phobia in patients with atopic eczema. Br. J. Dermatol. (2000) 142:931-936.
9. KRUTMANN J, MORITA A: Therapeutic photomedicine: Phototherapy. In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):2469-2477.
10. HÖNIGSMANN H, SZEIMIES RM, KNOBLER R et al.: Photochemotherapy and photodynamic therapy. In: Fitzpatrick's Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):2477-2493.
11. ATAKAN N, ERDEM C: The efficacy, tolerability and safety of a new oral formulation of Sandimmun - Sandimmun Neoral in severe refractory atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. (1998) 11:240-246.
12. RUZICKA T, BIEBER T, SCHOPF E et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. (1997) 337:816-821.
13. REITAMO S, WOLLENBERG A, SCHOPF E et al.: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch. Dermatol. (2000) 136:999-1006.
14. PALLER A, EICHENFIELD LF, LEUNG DY et al.: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J. Am. Acad. Dermatol. (2001) 44:547-557.
15. CHRISTOPHERS E, MROWIETZ U. Psoriasis. In: Fitzpatrick's Dermatalogy in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds), McGraw-Hill, New York, USA (2003):407-427.
16. ALTMEYER P, MATTHES U, PAWLAK F et al.: Antipsoriatic effect of fumaric acid derivatives: Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. (1994) 30:997-1081.
17. KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. (2002) 46:1-23.
18. ELLIS CN, KRUEGER JG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. (2001) 345:248-255.
19. GOTTLIEB AB, KRUEGER JG, WITTKOWSKI K et al.: Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. (2002) 38:591-600.
20. CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet (2001) 357:1842-1847.
21. MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet (2000) 356:385-390.
22. KRUEGER JG, WALTERS IB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high affinity interleukin 2 receptor) on T cells by administration of humanized anti-TAC antibody to patients with psoriasis. J. Am. Acad. Dermatol. (2000) 43:448-458.
23. ARAI T, KOYOMA Y, SUENAGA T et al.: Ascomycin, an antifungal antibiotic. J. Antibiot. SerA (1962) 15:231-234.
24. STUETZ A, GRASSBERGER M, MEINGASSNER JG: Entstehungsgeschichte und präklinisches Profil von Pimecrolimus. Hautarzt (2003) 54:405-412.
25. STUETZ A, GRASSBERGER M, BAUMANN K et al.: Immunophilins as drug targets, In: Perspectives in Medicinal Chemistry. Testa B, Kyburz E, Fuhrer W et al.: (Eds), Verlag Helvetica Chimica Acta, Basel, Weinheim, Verlag Chemie, (1993):427-443.
26. GRASSBERGER M, RAPPERSBERGER K, MEINGASSNER JG et al.: Ascomycins, In: Psoriasis. Roenigk HH, Maibach H (Eds), Marcel Dekker, New York NY, USA (1998):769-779.
27. PAUL C, GRAEBER M, STUETZ A: Ascomycins. Promising agents for the treatment of inflammatory skin diseases. Expert Opin. Investig. Drugs (2000) 9:69-77.
28. MEINGASSNER JG, STUETZ A: Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int. Arch. Allergy Immunol. (1992) 99:486-489.
29. MEINGASSNER JG, STUETZ A: Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases. J. Invest. Dermatol. (1992) 98:851-855.
30. RAPPERSBERGER K, MEINGASSNER JG, FIALLA R et al.: Clearing of psoriasis by a novel immunosuppressive macrolide. J. Invest. Dermatol. (1996) 106:701-710.
31. GRASSBERGER M, BAUMRUKER T, ENZ A et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br. J. Dermatol. (1999) 141:264-273.
32. MEINGASSNER JG, GRASSBERGER M, FAHRNGRUBER H et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br. J. Dermatol. (1997) 137:568-576.
33. STUETZ A, GRASSBERGER M, MEINGASSNER JG: Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity Semin. Cutan. Med. Surg. (2001) 20:233-241.
34. VAN LEENT EJM, GRÄBER M, THURSTON M et al.: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of aropic dermatitis. Arch. Dermatol. (1998) 134:805-809.
35. HARPER J, GREEN A, SCOTT G et al.: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. (2001) 144:781-787.
36. LUGER TA VAN LEENT EJM, GRAEBER M et al.: SDZ-ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. (2001) 144:788-794.
37. HO V, GUPTA A, KAUFMANN R et al.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. (2003) 142:155-162.
38. ALLEN BR, LAKHANPAUL M, MORRIS A et al.: Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch. Dis. Child. (2003) 88(11):969-973.
39. WAHN U, BOS JD, GOODFIELD M et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 110:e2.
40. MEURER M, FÖLSTER-HOLST R, WOZEL G et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology (2002) 205:271-277.
41. KAPP A, PAPP K, BINGHAM A et al.: Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J. Allergy Clin. Immunol. (2002) 110:277-284.
42. LUGER TA VAN LEENT EJM, GRAEBER M et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. (2001) 144:788-794.
43. EICHENFIELD LF, LUCKY AW, BOGUNEIWICZ M et al.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. (2002) 46:495-504.
44. QUEILLE-ROUSSEL C, PAUL C, DUTEIL L et al.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomized, double-blind controlled study. Br. J. Dermatol. (2001) 144:507-513.
45. VAN LEENT EJM, EBELIN ME, BURTIN P et al.: Low systemic exposure after repeated topical application of pimecrolimus (Elidel® , SDZ ASM 981) in patients with atopic dermatitis. Dermatology (2002) 204:63-68.
46. ALLEN BR, LAKHANPAUL M, MORRIS et al.: Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch. Dis. Child. (2003) 88:969-973.
47. ALLEN R, DAVIES T, BOS JD et al.: SDZ ASM 981: Pharmacokinetics in adults and children. J. Eur. Acad. Dermatol. Venereol. (2000) 14(Suppl. 1):91-92 (Abstract).
48. VAN LEENT EJM, DEVRIES JC, EBELIN ME et al.: Low blood concentrations of pimecrolimus (SDZ ASM 981) in adult atopic dermatitis patients treated topically for up to 1 year. 60th Annual Meeting of the Ameican Academy of Dermatology, New Orleans, (2002) (Abstract).
49. LAKHANPAUL M, DAVIES T, ALLEN B et al.: Pimecrolimus (SDZ ASM 981) cream 1%: Minimal systemic absorption in infants with atopic dermatitis during long-term treatment. Ann. Dermatol. Venereol. (2002) 129:1S415 (Abstract).
50. DAVIES T, ALLEN R, CARDNO M et al.: Low systemic SDZ ASM 981 concentrations in 3 months-2 year old children with extensive atopic dermatitis treated with 1% cream. Br. J. Dermatol. (2000) 143:75-76 (Abstract).
51. EICHENFIELD LF: Safety, pharmacokinetics, tolerability, and efficacy of topical SDZ ASM 981 (pimecrolimus) and FK506 (tacrolimus) in pediatric atopic dermatitis: A comparison of clinical studies. International Symposium on Atopic Dermatitis, Portland, Oregon September 6-9 (2001) (Abstract).
52. GRAHAM-BAOWN RAC, GRASSBERGER M: Pimecrolimus: a review of pre-clinical and clinical data. Int. J. Clin. Pract. (2003) 57:319-327.
53. RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol. (2002) 119:876-887.
54. HANIFIN J, FLEMING C, KORMAN N et al.: Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a dear dose-response effect. J. Invest. Dermatol. (2003) 121:1240 (Abstract).
55. WINISKI A, WANG S, SCHWENDINGER, B et al.: Effect of pimecrolimus, tacrolimus, cyclosporin A, betamethasone 17-valerate, dexamethasone and hydrocortisone on cytokine production and T-cell proliferation induced in human peripheral blood mononuclear cells (conference abstract). J. Invest. Dermatol. (2003) 121(No. 1): Abstract 1225.
56. KALTHOFF FS, CHUNG J, STUETZ A: Pimecrolimus inhibits upregulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cell. Clin. Exp. Immunol. (2002) 130:85-92.
57. HULTSCH T, MÜLLER KD, MEINGASSNER JG et al.: Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesiszed cytokines in RBL 2H3 mast cels in an immunophilin-dependent manner. Arch. Dermatol. Res. (1998) 290:501-507.
58. ZUBERBIER T, CHONG SU, GRUNOW K et al.: The ascomycin macrolactam pimecrolimus (Elidel®, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J. Allergy Clin. Immunol. (2001) 108:275-280.
59. KALTHOFF FS, CHUNG J, MUSSER P et al.: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin. Exp. Immunol. (2003) 133:350-359.
60. MEINGASSNER JG, KOWALSKY E, SCHWENDINGER H et al.: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol. (2003) 149:853-857.
61. HOETZENEGGER W, MEINGASSNER JG, ECKER R et al: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J. Invest. Dermatol. (2003) (In Press).
62. MEINGASSNER JG, FAHRNGRUBER H, BAVANDI A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. J. Invest. Dermatol. (2003) 121:77-80.
63. MEINGASSNER JG, FAHRNGRUBER H, SCHWEITZER A et al.: Pimecrolimus inhibits allergic contact dermatitis in rodents without affecting draining lymph nodes, different to tacrolimus. J. Jnvest. Dermatol. (2002) 119-343 (Conference Abstract).
64. NECKERMANN G, BAVANDI A, MEINGASSNER JG: Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br. J. Dermatol. (2000) 142:669-679.
65. MAHL A, ROMAN D, COURT M, VIT P et al.: Pimecrolimus shows in contrast to tacrolimus and cyclosporine only marginal effects on immunization at oral administration in a rat model. J. Invest. Dermatol. (2003) 121(1) (Abstract 1226).
66. BILLICH A, ASCHAUER H, ASZODY A et al.: Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharmaceutics (2004) 269:29-35.
67. KOIVUKANAGAS V, KARVONEN J, RISTELI J et al.: Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br. J. Dermatol. (1995) 132:66-68.
68. HAAPASAARI KM, RISTELI J, KARVONEN J et al.: Effect of hydrocortisone methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol. (1997) 135:1104-1110.
69. CHEILL P, TOFTE S, MACNAUL R et al.: SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. J. Eur. Acad. Dermatol. Venereol. (2000) 14(Suppl. 1):128 (Abstract).
70. QUEILLE-ROUSSEL C, GRAEBER M, THURSTON M et al.: SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm. (2000) 42:349-350.
71. AMROL D, KEITEL D, HAGAMAN D, MURRAY J: Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann. Allergy Asthma Immunol. (2003) 91:563-566.
72. MROWIETZ U, BRAEUTIGAM M, GRAEBER M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol. (1998) 139:992-996.
73. MROWIETZ U, WUSTLICH S, HOEXTER G et al.: Pimecrolimus (Elidel®, SDZ ASM 981) ointment is effective in psoriasis without occlusion (conference abstract) J. Eur. Acad. Dermatol. Venereol. (2001) 15(Suppl. 2):244.
74. BROWNELL I, QUAN LT, HSU S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J. (2003) 9:13.
75. GRIFFITHS C, DUBERTRET L, GOTTLIEB A: Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. J. Invest Dermatol. (2003) 121:0301 (Abstract).
76. LUCKY A, MARSHALL K, BUSH C et al.: SDZ ASM 981 cream 1% is effective and safe in children and adolescents with atopic dermatitis. Clin. Exp. Dermatol. (2001) 26:214 (Abstract).
77. MEURER M, BRÄUTIGAM M: Pimecrolimus (SDZ ASM 981) cream reduces the need for corticosteroids in the long-term management of atopic dermatitis in adults (Abstract). Presented in the 60th Annual Meeting of the American Academy of Dermatology New Orleas, LA. USA (2002) Poster no. 108.
78. WAHN U, MOLLOY SA GRAEBER M et al.: SDZ ASM 981 cream 1%: a new approach to long-term management of atopic dermatitis. J. Invest. Dermatol. (2001) 117(2):533 (Abstract).
79. WHALLEY D, MCKENNA S, HUELS J et al.: The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of pediatric atopic dermatitis: Results of two 6-week randomized double-blind vehicle-controlled clinical trials in the US (abstract). J. Eur. Acad. Dermatol. Venereol. (2001) 15(Suppl. 2):S112.
80. BOGUNIEWICZ M, EICHENFIELD L, HONIG P et al.: Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is safe in the long-term management of atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. (2001) 15(Suppl. 2):S110 (Abstract).
81. HANIFIN J. HO V, KAUFMANN P, KAPP A et al.: Pimecrolimus (SDZ ASM 981) cream: Good tolerability in paediatric patients. Ann. Dermatol. Venereol. (2002) 129:1S411 (Abstract).
82. WOLFF K, CARO I, MURRELL D et al.: Safety profile of oral pimecrolimus in atopic eczema and psoriasis: A pooled analysis form two dose-finding studies. J. Invest. Dermatol. (2003) 121:1245 (Abstract).